+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Ewing's Sarcoma Treatment Market 2022-2026

  • PDF Icon

    Report

  • 120 Pages
  • April 2022
  • Region: Global
  • TechNavio
  • ID: 5574255
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher has been monitoring the Ewing's sarcoma treatment market and it is poised to grow by $302.5 million during 2022-2026 progressing at a CAGR of 5.9% during the forecast period. The report on the Ewing's sarcoma treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by growing awareness about and funding for Ewing's sarcoma, regulatory incentives, and financial assistance programs and reimbursements schemes.

The Ewing's sarcoma treatment market analysis includes the type segment and geographic landscape.

The Ewing's sarcoma treatment market is segmented as below:


By Type

  • Combination therapy
  • Monotherapy

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the strong pipeline as one of the prime reasons driving the Ewing's sarcoma treatment market growth during the next few years. Also, the emergence of regenerative therapies and the advent of CRISPR-CAS9 technology will lead to sizable demand in the market.

The report on Ewing's sarcoma treatment market covers the following areas:

  • Ewing's sarcoma treatment market sizing
  • Ewing's sarcoma treatment market forecast
  • Ewing's sarcoma treatment market industry analysis

The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Ewing's sarcoma treatment market vendors that include Advenchen Laboratories LLC, Amneal Pharmaceuticals Inc., Baxter International Inc., Bristol Myers Squibb Co., Cellectar Biosciences Inc., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, Gradalis Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., PharmaMar SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. Also, the Ewing's sarcoma treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
Exhibit 06: Executive Summary - Chart on Incremental Growth
Exhibit 07: Executive Summary - Data Table on Incremental Growth
Exhibit 08: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 09: Parent market
Exhibit 10: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 11: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 12: Market segments
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021-2026
Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
4.1 Five forces summary
Exhibit 17: Five forces analysis - Comparison between2021 and 2026
4.2 Bargaining power of buyers
Exhibit 18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
4.3 Bargaining power of suppliers
Exhibit 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
4.4 Threat of new entrants
Exhibit 20: Threat of new entrants - Impact of key factors in 2021 and 2026
4.5 Threat of substitutes
Exhibit 21: Threat of substitutes - Impact of key factors in 2021 and 2026
4.6 Threat of rivalry
Exhibit 22: Threat of rivalry - Impact of key factors in 2021 and 2026
4.7 Market condition
Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Type
5.1 Market segments
Exhibit 24: Chart on Type - Market share 2021-2026 (%)
Exhibit 25: Data Table on Type - Market share 2021-2026 (%)
5.2 Comparison by Type
Exhibit 26: Chart on Comparison by Type
Exhibit 27: Data Table on Comparison by Type
5.3 Combination therapy - Market size and forecast 2021-2026
Exhibit 28: Chart on Combination therapy - Market size and forecast 2021-2026 ($ million)
Exhibit 29: Data Table on Combination therapy - Market size and forecast 2021-2026 ($ million)
Exhibit 30: Chart on Combination therapy - Year-over-year growth 2021-2026 (%)
Exhibit 31: Data Table on Combination therapy - Year-over-year growth 2021-2026 (%)
5.4 Monotherapy - Market size and forecast 2021-2026
Exhibit 32: Chart on Monotherapy - Market size and forecast 2021-2026 ($ million)
Exhibit 33: Data Table on Monotherapy - Market size and forecast 2021-2026 ($ million)
Exhibit 34: Chart on Monotherapy - Year-over-year growth 2021-2026 (%)
Exhibit 35: Data Table on Monotherapy - Year-over-year growth 2021-2026 (%)
5.5 Market opportunity by Type
Exhibit 36: Market opportunity by Type ($ million)
6 Customer Landscape
6.1 Customer landscape overview
Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
7.1 Geographic segmentation
Exhibit 38: Chart on Market share By Geographical Landscape 2021-2026 (%)
Exhibit 39: Data Table on Market share By Geographical Landscape 2021-2026 (%)
7.2 Geographic comparison
Exhibit 40: Chart on Geographic comparison
Exhibit 41: Data Table on Geographic comparison
7.3 North America - Market size and forecast 2021-2026
Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
7.4 Europe - Market size and forecast 2021-2026
Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
7.5 Asia - Market size and forecast 2021-2026
Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
7.6 Rest of World (ROW) - Market size and forecast 2021-2026
Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
7.7 US - Market size and forecast 2021-2026
Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
7.8 Canada - Market size and forecast 2021-2026
Exhibit 62: Chart on Canada - Market size and forecast 2021-2026 ($ million)
Exhibit 63: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
Exhibit 64: Chart on Canada - Year-over-year growth 2021-2026 (%)
Exhibit 65: Data Table on Canada - Year-over-year growth 2021-2026 (%)
7.9 UK - Market size and forecast 2021-2026
Exhibit 66: Chart on UK - Market size and forecast 2021-2026 ($ million)
Exhibit 67: Data Table on UK - Market size and forecast 2021-2026 ($ million)
Exhibit 68: Chart on UK - Year-over-year growth 2021-2026 (%)
Exhibit 69: Data Table on UK - Year-over-year growth 2021-2026 (%)
7.10 Germany - Market size and forecast 2021-2026
Exhibit 70: Chart on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 71: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 72: Chart on Germany - Year-over-year growth 2021-2026 (%)
Exhibit 73: Data Table on Germany - Year-over-year growth 2021-2026 (%)
7.11 Japan - Market size and forecast 2021-2026
Exhibit 74: Chart on Japan - Market size and forecast 2021-2026 ($ million)
Exhibit 75: Data Table on Japan - Market size and forecast 2021-2026 ($ million)
Exhibit 76: Chart on Japan - Year-over-year growth 2021-2026 (%)
Exhibit 77: Data Table on Japan - Year-over-year growth 2021-2026 (%)
7.12 China - Market size and forecast 2021-2026
Exhibit 78: Chart on China - Market size and forecast 2021-2026 ($ million)
Exhibit 79: Data Table on China - Market size and forecast 2021-2026 ($ million)
Exhibit 80: Chart on China - Year-over-year growth 2021-2026 (%)
Exhibit 81: Data Table on China - Year-over-year growth 2021-2026 (%)
7.13 Market opportunity By Geographical Landscape
Exhibit 82: Market opportunity By Geographical Landscape ($ million)
8 Drivers, Challenges, and Trends
8.1 Market drivers
8.2 Market challenges
8.3 Impact of drivers and challenges
Exhibit 83: Impact of drivers and challenges in 2021 and 2026
8.4 Market trends
9 Vendor Landscape
9.1 Overview
9.2 Vendor landscape
Exhibit 84: Overview on Criticality of inputs and Factors of differentiation
9.3 Landscape disruption
Exhibit 85: Overview on factors of disruption
9.4 Industry risks
Exhibit 86: Impact of key risks on business
10 Vendor Analysis
10.1 Vendors covered
Exhibit 87: Vendors covered
10.2 Market positioning of vendors
Exhibit 88: Matrix on vendor position and classification
10.3 Amneal Pharmaceuticals Inc.
Exhibit 89: Amneal Pharmaceuticals Inc. - Overview
Exhibit 90: Amneal Pharmaceuticals Inc. - Business segments
Exhibit 91: Amneal Pharmaceuticals Inc. - Key news
Exhibit 92: Amneal Pharmaceuticals Inc. - Key offerings
Exhibit 93: Amneal Pharmaceuticals Inc. - Segment focus
10.4 Baxter International Inc.
Exhibit 94: Baxter International Inc. - Overview
Exhibit 95: Baxter International Inc. - Business segments
Exhibit 96: Baxter International Inc. - Key offerings
Exhibit 97: Baxter International Inc. - Segment focus
10.5 Bristol Myers Squibb Co.
Exhibit 98: Bristol Myers Squibb Co. - Overview
Exhibit 99: Bristol Myers Squibb Co. - Product / Service
Exhibit 100: Bristol Myers Squibb Co. - Key offerings
10.6 Eli Lilly and Co.
Exhibit 101: Eli Lilly and Co. - Overview
Exhibit 102: Eli Lilly and Co. - Product / Service
Exhibit 103: Eli Lilly and Co. - Key offerings
10.7 Merck and Co. Inc.
Exhibit 104: Merck and Co. Inc. - Overview
Exhibit 105: Merck and Co. Inc. - Business segments
Exhibit 106: Merck and Co. Inc. - Key news
Exhibit 107: Merck and Co. Inc. - Key offerings
Exhibit 108: Merck and Co. Inc. - Segment focus
10.8 Novartis AG
Exhibit 109: Novartis AG - Overview
Exhibit 110: Novartis AG - Business segments
Exhibit 111: Novartis AG - Key offerings
Exhibit 112: Novartis AG - Segment focus
10.9 Pfizer Inc.
Exhibit 113: Pfizer Inc. - Overview
Exhibit 114: Pfizer Inc. - Product / Service
Exhibit 115: Pfizer Inc. - Key news
Exhibit 116: Pfizer Inc. - Key offerings
10.10 PharmaMar SA
Exhibit 117: PharmaMar SA - Overview
Exhibit 118: PharmaMar SA - Business segments
Exhibit 119: PharmaMar SA - Key news
Exhibit 120: PharmaMar SA - Key offerings
Exhibit 121: PharmaMar SA - Segment focus
10.11 Teva Pharmaceutical Industries Ltd.
Exhibit 122: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 123: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 124: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 125: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 126: Teva Pharmaceutical Industries Ltd. - Segment focus
10.12 Viatris Inc.
Exhibit 127: Viatris Inc. - Overview
Exhibit 128: Viatris Inc. - Business segments
Exhibit 129: Viatris Inc. - Key offerings
Exhibit 130: Viatris Inc. - Segment focus
11 Appendix
11.1 Scope of the report
11.2 Inclusions and exclusions checklist
Exhibit 131: Inclusions checklist
Exhibit 132: Exclusions checklist
11.3 Currency conversion rates for US$
Exhibit 133: Currency conversion rates for US$
11.4 Research methodology
Exhibit 134: Research methodology
Exhibit 135: Validation techniques employed for market sizing
Exhibit 136: Information sources
11.5 List of abbreviations
Exhibit 137: List of abbreviations

List of Exhibits

Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Type
Exhibits 6: Executive Summary - Chart on Incremental Growth
Exhibits 7: Executive Summary - Data Table on Incremental Growth
Exhibits 8: Executive Summary - Chart on Vendor Market Positioning
Exhibits 9: Parent market
Exhibits 10: Market Characteristics
Exhibits 11: Offerings of vendors included in the market definition
Exhibits 12: Market segments
Exhibits 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
Exhibits 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
Exhibits 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
Exhibits 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
Exhibits 17: Five forces analysis - Comparison between2021 and 2026
Exhibits 18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
Exhibits 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
Exhibits 20: Threat of new entrants - Impact of key factors in 2021 and 2026
Exhibits 21: Threat of substitutes - Impact of key factors in 2021 and 2026
Exhibits 22: Threat of rivalry - Impact of key factors in 2021 and 2026
Exhibits 23: Chart on Market condition - Five forces 2021 and 2026
Exhibits 24: Chart on Type - Market share 2021-2026 (%)
Exhibits 25: Data Table on Type - Market share 2021-2026 (%)
Exhibits 26: Chart on Comparison by Type
Exhibits 27: Data Table on Comparison by Type
Exhibits 28: Chart on Combination therapy - Market size and forecast 2021-2026 ($ million)
Exhibits 29: Data Table on Combination therapy - Market size and forecast 2021-2026 ($ million)
Exhibits 30: Chart on Combination therapy - Year-over-year growth 2021-2026 (%)
Exhibits 31: Data Table on Combination therapy - Year-over-year growth 2021-2026 (%)
Exhibits 32: Chart on Monotherapy - Market size and forecast 2021-2026 ($ million)
Exhibits 33: Data Table on Monotherapy - Market size and forecast 2021-2026 ($ million)
Exhibits 34: Chart on Monotherapy - Year-over-year growth 2021-2026 (%)
Exhibits 35: Data Table on Monotherapy - Year-over-year growth 2021-2026 (%)
Exhibits 36: Market opportunity by Type ($ million)
Exhibits 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 38: Chart on Market share By Geographical Landscape 2021-2026 (%)
Exhibits 39: Data Table on Market share By Geographical Landscape 2021-2026 (%)
Exhibits 40: Chart on Geographic comparison
Exhibits 41: Data Table on Geographic comparison
Exhibits 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
Exhibits 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
Exhibits 44: Chart on North America - Year-over-year growth 2021-2026 (%)
Exhibits 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
Exhibits 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
Exhibits 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
Exhibits 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
Exhibits 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
Exhibits 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
Exhibits 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
Exhibits 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
Exhibits 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
Exhibits 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibits 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibits 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibits 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibits 58: Chart on US - Market size and forecast 2021-2026 ($ million)
Exhibits 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
Exhibits 60: Chart on US - Year-over-year growth 2021-2026 (%)
Exhibits 61: Data Table on US - Year-over-year growth 2021-2026 (%)
Exhibits 62: Chart on Canada - Market size and forecast 2021-2026 ($ million)
Exhibits 63: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
Exhibits 64: Chart on Canada - Year-over-year growth 2021-2026 (%)
Exhibits 65: Data Table on Canada - Year-over-year growth 2021-2026 (%)
Exhibits 66: Chart on UK - Market size and forecast 2021-2026 ($ million)
Exhibits 67: Data Table on UK - Market size and forecast 2021-2026 ($ million)
Exhibits 68: Chart on UK - Year-over-year growth 2021-2026 (%)
Exhibits 69: Data Table on UK - Year-over-year growth 2021-2026 (%)
Exhibits 70: Chart on Germany - Market size and forecast 2021-2026 ($ million)
Exhibits 71: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
Exhibits 72: Chart on Germany - Year-over-year growth 2021-2026 (%)
Exhibits 73: Data Table on Germany - Year-over-year growth 2021-2026 (%)
Exhibits 74: Chart on Japan - Market size and forecast 2021-2026 ($ million)
Exhibits 75: Data Table on Japan - Market size and forecast 2021-2026 ($ million)
Exhibits 76: Chart on Japan - Year-over-year growth 2021-2026 (%)
Exhibits 77: Data Table on Japan - Year-over-year growth 2021-2026 (%)
Exhibits 78: Chart on China - Market size and forecast 2021-2026 ($ million)
Exhibits 79: Data Table on China - Market size and forecast 2021-2026 ($ million)
Exhibits 80: Chart on China - Year-over-year growth 2021-2026 (%)
Exhibits 81: Data Table on China - Year-over-year growth 2021-2026 (%)
Exhibits 82: Market opportunity By Geographical Landscape ($ million)
Exhibits 83: Impact of drivers and challenges in 2021 and 2026
Exhibits 84: Overview on Criticality of inputs and Factors of differentiation
Exhibits 85: Overview on factors of disruption
Exhibits 86: Impact of key risks on business
Exhibits 87: Vendors covered
Exhibits 88: Matrix on vendor position and classification
Exhibits 89: Amneal Pharmaceuticals Inc. - Overview
Exhibits 90: Amneal Pharmaceuticals Inc. - Business segments
Exhibits 91: Amneal Pharmaceuticals Inc. - Key news
Exhibits 92: Amneal Pharmaceuticals Inc. - Key offerings
Exhibits 93: Amneal Pharmaceuticals Inc. - Segment focus
Exhibits 94: Baxter International Inc. - Overview
Exhibits 95: Baxter International Inc. - Business segments
Exhibits 96: Baxter International Inc. - Key offerings
Exhibits 97: Baxter International Inc. - Segment focus
Exhibits 98: Bristol Myers Squibb Co. - Overview
Exhibits 99: Bristol Myers Squibb Co. - Product / Service
Exhibits 100: Bristol Myers Squibb Co. - Key offerings
Exhibits 101: Eli Lilly and Co. - Overview
Exhibits 102: Eli Lilly and Co. - Product / Service
Exhibits 103: Eli Lilly and Co. - Key offerings
Exhibits 104: Merck and Co. Inc. - Overview
Exhibits 105: Merck and Co. Inc. - Business segments
Exhibits 106: Merck and Co. Inc. - Key news
Exhibits 107: Merck and Co. Inc. - Key offerings
Exhibits 108: Merck and Co. Inc. - Segment focus
Exhibits 109: Novartis AG - Overview
Exhibits 110: Novartis AG - Business segments
Exhibits 111: Novartis AG - Key offerings
Exhibits 112: Novartis AG - Segment focus
Exhibits 113: Pfizer Inc. - Overview
Exhibits 114: Pfizer Inc. - Product / Service
Exhibits 115: Pfizer Inc. - Key news
Exhibits 116: Pfizer Inc. - Key offerings
Exhibits 117: PharmaMar SA - Overview
Exhibits 118: PharmaMar SA - Business segments
Exhibits 119: PharmaMar SA - Key news
Exhibits 120: PharmaMar SA - Key offerings
Exhibits 121: PharmaMar SA - Segment focus
Exhibits 122: Teva Pharmaceutical Industries Ltd. - Overview
Exhibits 123: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibits 124: Teva Pharmaceutical Industries Ltd. - Key news
Exhibits 125: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibits 126: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibits 127: Viatris Inc. - Overview
Exhibits 128: Viatris Inc. - Business segments
Exhibits 129: Viatris Inc. - Key offerings
Exhibits 130: Viatris Inc. - Segment focus
Exhibits 131: Inclusions checklist
Exhibits 132: Exclusions checklist
Exhibits 133: Currency conversion rates for US$
Exhibits 134: Research methodology
Exhibits 135: Validation techniques employed for market sizing
Exhibits 136: Information sources
Exhibits 137: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global Ewing's sarcoma treatment market: Advenchen Laboratories LLC, Amneal Pharmaceuticals Inc., Baxter International Inc., Bristol Myers Squibb Co., Cellectar Biosciences Inc., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, Gradalis Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., PharmaMar SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.

Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is strong pipeline.`

According to the report, one of the major drivers for this market is the growing awareness about and funding for Ewing's sarcoma.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.


Companies Mentioned

A selection of companies mentioned in this report includes:

  • Advenchen Laboratories LLC
  • Amneal Pharmaceuticals Inc.
  • Baxter International Inc.
  • Bristol Myers Squibb Co.
  • Cellectar Biosciences Inc.
  • Daiichi Sankyo Co. Ltd.
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Gradalis Inc.
  • Merck and Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • PharmaMar SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.